Results 1 to 10 of about 3,620 (131)
Journal of the American Heart Association, 2023 Background The optimal dose of tenecteplase in acute ischemic stroke remains to be defined. We present a pooled analysis of the 2 NOR‐TESTs (Norwegian Tenecteplase Stroke Trials) exploring the efficacy and safety of tenecteplase, 0.4 mg/kg.
Nicola Logallo +2 more
exaly +3 more sources
Real-world efficacy and safety of Tenecteplase versus Alteplase in acute ischemic stroke: a propensity score-matched analysis [PDF]
Frontiers in NeurologyBackgroundReal-world evidence comparing Tenecteplase and Alteplase for acute ischemic stroke (AIS) remains limited. This study aimed to evaluate the comparative efficacy and safety of these thrombolytic agents in an unselected patient cohort.MethodsThis ...
Peng Zhang, Liangyun Sun, Liangxue Wang
doaj +2 more sources
Thrombus Migration After Tenecteplase Versus Alteplase in Acute Large Vessel Occlusion [PDF]
Journal of StrokeBackground and Purpose In patients with large vessel occlusion (LVO), intravenous thrombolysis (IVT) frequently alters thrombus location; however, the clinical impact of this phenomenon remains unclear.
Lu Wang +14 more
doaj +2 more sources
Tenecteplase versus standard medical treatment for minor stroke due to anterior-circulation medium-vessel occlusion: a multicenter observational study [PDF]
Frontiers in NeurosciencePurposeTo assess whether intravenous tenecteplase is associated with improved clinical outcomes compared with standard medical treatment (SMT) in patients with minor acute ischemic stroke (AIS) caused by medium-vessel occlusion (MeVO).MethodsWe conducted
He Jiang +4 more
doaj +2 more sources
Comprehensive Review of Tenecteplase for Thrombolysis in Acute Ischemic Stroke
Journal of the American Heart AssociationAlthough intravenous thrombolysis with alteplase remains the primary treatment for acute ischemic stroke, tenecteplase has shown potential advantages over alteplase.
Marc Fisher, Yunyun Xiong, Liyuan Wang
exaly +3 more sources
Trade‐Off Between Early Reperfusion and First‐Pass Effect With Tenecteplase Versus Alteplase Before Stroke Thrombectomy [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Early reperfusion and first‐pass effect are key procedural end points in large‐vessel occlusion stroke thrombectomy. Because of greater fibrin specificity, tenecteplase may achieve higher early reperfusion rates compared with alteplase, yet ...
Tyler M. Bielinski +9 more
doaj +2 more sources
Frontiers in Neurology, 2023 BackgroundThe optimal dose of tenecteplase vs. alteplase for acute ischemic stroke (AIS) has yet to be established. Therefore, we included the latest randomized controlled trials (RCT) to assess the efficacy and safety of different doses of tenecteplase ...
Huo Liang +8 more
doaj +1 more source
Medicina, 2022 Background and Objectives: The study aimed to investigate the efficacy of intravenous thrombolysis with Tenecteplase before thrombectomy for acute ischemic stroke (AIS) patients compared with previous results using Alteplase.
Agnete Teivane +6 more
doaj +1 more source
Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up?
Western Journal of Emergency Medicine, 2020 Alteplase is the only Food and Drug Administration-approved intravenous (IV) thrombolytic medication for acute ischemic stroke. However, multiple recent studies comparing tenecteplase and alteplase suggest that tenecteplase is at least as efficacious as ...
Tony Zitek, Ramsey Ataya, Isabel Brea
doaj +1 more source
Stroke: Vascular and Interventional Neurology, 2023 Introduction Tenecteplase is increasingly being used as a first‐line treatment for acute ischemic stroke after several randomized studies demonstrated its safety and efficacy, resulting in a massive increase in the number of published studies on this ...
Brendan Huang
doaj +1 more source